TapImmune Provides Update on PolyStart™ Vaccine Platform Applicable to Cancer and Infectious Disease
October 22 2014 - 8:30AM
Business Wire
Platform Technology is a novel platform for rapid development of
Vaccines for Cancer and Multiple Emerging Viral Threats including
Ebola, Enterovirus, and Smallpox.
TapImmune, Inc. (OTCBB:TPIV), provides an update on the status
of its PolyStartTM vaccine technology platform in light of recent
global concerns regarding pandemic infections and emerging viral
threats such as Ebola and Enterovirus. While the current focus of
the Company’s PolyStart technology is on TapImmune’s cancer program
(e.g., Her2/neu and folate receptor alpha antigens), the Company
none-the-less strongly reaffirms that this core technology has
widespread applicability in the development of vaccines for viral
disease.
The use of the Company’s PolyStart technology increases the
production of proprietary antigenic peptides of the vaccine by as
much as FOUR-fold, thereby increasing vaccine potency (presenting
more antigen), and potentially making manufacturing and
commercialization of large volume vaccines more cost effective.
While additional preclinical development is in progress, we
fundamentally believe that our technology will have a significant
impact in the development of vaccines for both cancer and emerging
viral-disease (e.g., Ebola, Enterovirus etc).
Successful proof-of-concept studies conducted in collaboration
with Mayo Clinic clearly demonstrated that human cells containing a
PolyStart construct containing vaccinia virus (“smallpox”) antigens
(antigenic peptides) could naturally express, process and present
these antigens on the cell surface and that cell surface
presentation occurred in a manner recognizable by immune system
cells (e.g., CD8+ killer T-cells). Importantly, CD8+ T-cells
recognizing a PolyStart-encoded antigenic peptide on the cell
surface will destroy that cell. In addition, T-cells recognizing
the antigenic peptide are stimulated to expand in number, thereby
providing a strong longer-lived capacity to destroy many more cells
infected with the virus.
TapImmune is actively seeking partnerships and collaborations
for development of PolyStart for the treatment of emerging viral
threats.
About TapImmune Inc.
TapImmune Inc. is an immunotherapy company specializing in the
development of innovative vaccine technologies for the treatment of
cancer and infectious disease. The Company’s vaccine compositions,
peptide or nucleic acid-based, comprise one or multiple naturally
processed epitopes (NPEs) designed to comprehensively stimulate a
patients’ killer T-cells, helper T-cells and to restore or further
augment antigen presentation by using proprietary nucleic
acid-based expression systems. The Company’s vaccine compositions
may be used as stand-alone medications or in combination with
current treatment modalities. Please visit the Company’s website at
www.tapimmune.com for details.
Safe Harbor Statement
This press release contains certain statements that may include
“forward-looking statements.” All statements other than statements
of historical fact included herein are “forward-looking
statements.” These forward-looking statements are often identified
by the use of forward-looking terminology such as “believes,”
“expects” or similar expressions, involving known and unknown risks
and uncertainties. Although the Company believes that the
expectations reflected in these forward-looking statements are
reasonable, they do involve assumptions, risks and uncertainties,
and these expectations may prove to be incorrect. You should not
place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. The Company's
actual results could differ materially from those anticipated in
these forward-looking statements as a result of a variety of
factors, including the risk factors discussed in the Company's
periodic reports that are filed with the Securities and Exchange
Commission and available on the SEC's website (http://www.sec.gov).
All forward-looking statements attributable to the Company or
persons acting on its behalf are expressly qualified in their
entirety by these risk factors. Other than as required under the
securities laws, the Company does not assume a duty to update these
forward-looking statements.
TapImmune Inc.Glynn Wilson, PH.D., 866-359-7541Chairman &
CEOorInvestor RelationsJ.Streicher
Capital, LLC.Robert GiordanoTel: 212-257-5495Cell:
917-327-3938rgiordano@jstreichercapital.com
TapImmune, Inc. (NASDAQ:TPIV)
Historical Stock Chart
From Mar 2024 to Apr 2024
TapImmune, Inc. (NASDAQ:TPIV)
Historical Stock Chart
From Apr 2023 to Apr 2024